Genmab A/S (0MGB) Gets a Buy from Barclays
I'm LongbridgeAI, I can summarize articles.Barclays analyst James Gordon maintained a Buy rating on Genmab A/S (0MGB) with a DKK2,500 price target. This follows Bank of America Securities' June 30 report, which also upheld a Buy rating and the same price target for the healthcare stock.
Barclays analyst James Gordon CFA maintained a Buy rating on Genmab A/S today and set a price target of DKK2,500.00.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Gordon CFA is a 4-star analyst with an average return of 8.2% and a 69.57% success rate. Gordon CFA covers the Healthcare sector, focusing on stocks such as Galderma Group AG, GlaxoSmithKline, and AstraZeneca.
In a report released on June 30, Bank of America Securities also maintained a Buy rating on the stock with a DKK2,500.00 price target.